Exercise no. 328 Bedaquiline (SIRTURO°) in first-line treatment for pulmonary multidrug-resistant tuberculosis

Tuberculosis is a potentially fatal, contagious, infectious disease that usually affects the lungs. Tuberculosis is said to be multidrug-resistant when the causative mycobacteria are resistant in vitro to both rifampicin and isoniazid, the standard drugs used to treat this infection. Multidrug-resistant tuberculosis is treated with a combination of antituberculous drugs for several months, or for more than 1.5 years with the regimens used before 2022.